Navigation Links
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Date:6/1/2009

at taribavirin could replace ribavirin as a cornerstone in the treatment of hepatitis C, but with the advantage of less anemia," said J. Michael Pearson, chairman and chief executive officer. "These encouraging results, coupled with Schering-Plough's option agreement for a license in Japan, could offer new alternatives for patients suffering from this disease and we will continue to pursue additional licensing and partnering opportunities in order to maximize this compound's potential."

The most common adverse events during treatment were fatigue, nausea, flu-like symptoms, headache and diarrhea. The incidence rates for these adverse events among treatment arms were generally comparable except with respect to diarrhea, where incidence of diarrhea was approximately twice as common in patients receiving taribavirin compared to patients receiving ribavirin. However, the diarrhea was generally mild and not treatment limiting for taribavirin or ribavirin patients.

About Taribavirin

Taribavirin is an investigational compound that has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the diagnosis, mitigation, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until approved for marketing by the FDA. Similar restrictions apply in other countries.

About Study 204

The Phase IIb trial is a U.S. multi-center, randomized, parallel, open-label study in 278 treatment-naive, genotype 1 patients evaluating taribavirin at weight-based doses of 20 mg/kg, 25 mg/kg, and 30 mg/kg per day in combination with pegylated interferon alfa-2b. The control group was administered weight-based dose ribavirin (800/1000/1200/1400mg daily) and pegylated interferon alfa-2b. Overall treatment duration is 48 weeks with a post-treatment follow-up period of 24 weeks.

In the Phase I
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DFB Sells Coria Labs to Valeant Pharmaceuticals
2. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
3. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... , July 23, 2014 ... SHPG ), the global specialty biopharmaceutical company, and ... announced a worldwide licensing and collaboration agreement for ... the potential treatment of both the central nervous ... Hunter syndrome (MPS II). This collaboration strengthens Shire,s ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, ... today announced that it will host a webcast on June 8, ... 6th at the 14th Congress of the European Hematology Association. ... www.micromet-inc.com . , , Forum: ...
... VIEW, Calif., June 2 VIVUS, Inc. (Nasdaq: ... therapies to address unmet needs in obesity, diabetes and ... featured in two podium presentations during the 69th Scientific ... from June 5-9, 2009 in New Orleans, Louisiana. ...
... June 2 BioGenex, a developer of innovative instruments ... molecular diagnostics, announced today that Abbott has entered into ... distribution agreement to market the Xmatrx(R) platform for the ... terms of the agreement Abbott customers will have the ...
Cached Biology Technology:Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 2Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 3Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 4Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 2Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 3Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays 2
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... study funded by the New Jersey Recovery Fund and ... of Planning and Public Policy at Rutgers University has ... skeptical about the likelihood of community-based rebuilding solutions. Of ... indicated they were "pessimistic" or "very pessimistic" that the ... be rebuilt better than they were before the storm; ...
(Date:7/24/2014)... life arose have been maintained in our cells today according ... published today in the Journal of Biological Chemistry ... in animals still perform ancient reactions thought to have been ... years ago. , The primordial soup theory suggests that life ... the combination of metals, gases from the atmosphere and some ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... reported preclinical study results, which demonstrate the ... cells (ADRCs) for the treatment of damaged ... tissue density and disc-specific extracellular matrix components ... animal model. The data were presented today ...
... Society (ACS) News Service Weekly PressPac with news from ACS, ... credit the individual journal or the American Chemical Society as ... IMMEDIATE RELEASE EXCEPT ARTICLE #5, which is embargoed for 9 ... PressPac Archive: ARTICLE ...
... and abnormalities in metabolism and diabetes has been suggested in ... Oxford, the Wellcome Trust Sanger Institute and the MRC Epidemiology ... involved in the way the body responds to the 24 ... sugar levels and an increased risk of type 2 diabetes. ...
Cached Biology News:Cytori reports benefit of adipose-derived regenerative cells in spinal disc model 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 3American Chemical Society's Weekly PressPac -- Dec. 3, 2008 4American Chemical Society's Weekly PressPac -- Dec. 3, 2008 5American Chemical Society's Weekly PressPac -- Dec. 3, 2008 6American Chemical Society's Weekly PressPac -- Dec. 3, 2008 7American Chemical Society's Weekly PressPac -- Dec. 3, 2008 8Discovery of new gene associated with diabetes risk suggests link with body clock 2
... DASGIP Overhead Drive for individual and ... for flexible agitation of DASGIP vessels, featuring ... impellers. ,Up to 16 overhead drives ... DASGIP Cultivation Systems fedbatch-pro® and cellferm-pro® for ...
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The system is especially dedicated ... standard system for Western blotting applications.,Fuiji's ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... the space and time dimensions of a streak ... microscope to open new horizons in biological imaging. ... excitation, the decay of a fluorescence emission can ... measured. Subtle changes in the local environment ...
Biology Products: